Literature DB >> 27387681

Significance of Vascular Resection and Reconstruction in Surgery for Hilar Cholangiocarcinoma: With Special Reference to Hepatic Arterial Resection and Reconstruction.

Ryusei Matsuyama1, Ryutaro Mori2, Yohei Ota2, Yuki Homma2, Takafumi Kumamoto2, Kazuhisa Takeda2, Daisuke Morioka2, Jiro Maegawa3, Itaru Endo2.   

Abstract

PURPOSE: The aim of this study was to assess the efficacy of combined resection and reconstruction (CRR) of the hepatic artery (HA) in surgery for hilar cholangiocarcinoma (HC). MATERIALS AND
METHOD: Among 172 patients who underwent surgical resection for HC, the following three groups were defined according to the type of vascular reconstruction: VR(-) group, in which neither CRR of the portal vein (PV) nor HA was performed (n = 74); VR-PV group, in which only CRR of the PV was required (n = 54); and VR-A group, in which CRR of the HA was performed either with or without CRR of the PV (n = 44). Clinicopathological variables and clinical outcomes were compared among the three groups.
RESULTS: Although the VR-A group showed significantly more advanced disease than other groups, the R0 resection rate was comparable among the three groups (VR(-), 74 %; VR-PV, 80 %; VR-A, 80 %). The 5-year disease-specific survival rate was also comparable among the three groups (VR(-), 45.6 %; VR-PV, 51.2 %; VR-A, 22.3 %), but tended to be worse in the VR-A group than in the other groups. A similar trend was observed in morbidity rate. Lymph node metastasis was more frequent in the VR-A group (59 %) than in the other groups (VR(-), 33.8 %; VR-PV, 50 %). In the VR-A group, lymph node metastasis (p = 0.004) and adjuvant chemotherapy (p = 0.006) were determined to represent independent prognostic factors for survival according to multivariate analysis.
CONCLUSION: CRR of the HA was considered efficacious in selected patients; however, long-term outcomes of the VR-A group seem unsatisfactory. Treatments additional to surgery may be necessary in cases requiring CRR of the HA.

Entities:  

Year:  2016        PMID: 27387681     DOI: 10.1245/s10434-016-5381-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  Hepatic Artery Resection for Bismuth Type III and IV Hilar Cholangiocarcinoma: Is Reconstruction Always Required?

Authors:  Hai-Jie Hu; Yan-Wen Jin; Rong-Xing Zhou; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  J Gastrointest Surg       Date:  2018-03-06       Impact factor: 3.452

2.  Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium.

Authors:  Gregory V Schimizzi; Linda X Jin; Jesse T Davidson; Bradley A Krasnick; Cecilia G Ethun; Timothy M Pawlik; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Sharon M Weber; Ahmed Salem; William G Hawkins; Steven M Strasberg; Maria B Doyle; William C Chapman; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Ryan C Fields
Journal:  HPB (Oxford)       Date:  2017-11-21       Impact factor: 3.647

3.  Utility of convex EUS for preoperative vascular evaluation of malignant biliary tract neoplasm.

Authors:  Akashi Fujita; Kazuo Hara; Nobumasa Mizuno; Susumu Hijioka; Takamichi Kuwahara; Nozomi Okuno; Yasuhiro Shimizu; Yoshiki Senda; Seiji Natsume; Yasumasa Niwa
Journal:  Mol Clin Oncol       Date:  2017-12-29

4.  Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Ryutaro Mori; Yohei Ota; Yuki Homma; Yasuhiro Yabusita; Seigo Hiratani; Takashi Murakami; Yu Sawada; Kentaro Miyake; Yasuhiro Shimizu; Takafumi Kumamoto; Itaru Endo
Journal:  Ann Surg Oncol       Date:  2022-01-07       Impact factor: 5.344

5.  Validation study of postoperative liver failure and mortality risk scores after liver resection for perihilar cholangiocarcinoma.

Authors:  Takehiro Noji; Satoko Uemura; Jimme K Wiggers; Kimitaka Tanaka; Yoshitsugu Nakanishi; Toshimichi Asano; Toru Nakamura; Takahiro Tsuchikawa; Keisuke Okamura; Pim B Olthof; William R Jarnagin; Thomas M van Gulik; Satoshi Hirano
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

6.  Surgical Outcomes for Perihilar Cholangiocarcinoma with Vascular Invasion.

Authors:  Ryota Higuchi; Takehisa Yazawa; Shuichiro Uemura; Wataru Izumo; Takehiro Ota; Kosuke Kiyohara; Toru Furukawa; Hiroto Egawa; Masakazu Yamamoto
Journal:  J Gastrointest Surg       Date:  2018-09-10       Impact factor: 3.452

Review 7.  Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art.

Authors:  Lynn E Nooijen; Rutger-Jan Swijnenburg; Heinz-Josef Klümpen; Joanne Verheij; Geert Kazemier; Thomas M van Gulik; Joris I Erdmann
Journal:  Visc Med       Date:  2021-01-07

8.  ASO Author Reflections: Hilar Cholangiocarcinoma.

Authors:  Kevin C Soares; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2021-05-04       Impact factor: 4.339

9.  Transhepatic Hilar Approach for Perihilar Cholangiocarcinoma: Significance of Early Judgment of Resectability and Safe Vascular Reconstruction.

Authors:  Naohisa Kuriyama; Shuji Isaji; Akihiro Tanemura; Yusuke Iizawa; Hiroyuki Kato; Yasuhiro Murata; Yoshinori Azumi; Masashi Kishiwada; Shugo Mizuno; Masanobu Usui; Hiroyuki Sakurai
Journal:  J Gastrointest Surg       Date:  2016-11-28       Impact factor: 3.452

10.  Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma.

Authors:  Eva Braunwarth; Stefan Stättner; Margot Fodor; Benno Cardini; Thomas Resch; Rupert Oberhuber; Daniel Putzer; Reto Bale; Manuel Maglione; Christian Margreiter; Stefan Schneeberger; Dietmar Öfner; Florian Primavesi
Journal:  Eur Surg       Date:  2018-05-17       Impact factor: 0.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.